Compare ADMA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADMA | XNCR |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2012 | 2013 |
| Metric | ADMA | XNCR |
|---|---|---|
| Price | $9.83 | $27.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $25.67 | $22.33 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 0.35 | N/A |
| Revenue | $42,219,783.00 | ★ $125,576,000.00 |
| Revenue This Year | $27.46 | N/A |
| Revenue Next Year | $22.11 | $4.80 |
| P/E Ratio | $27.89 | ★ N/A |
| Revenue Growth | ★ 43.85 | 13.65 |
| 52 Week Low | $7.21 | $7.72 |
| 52 Week High | $20.46 | $27.70 |
| Indicator | ADMA | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 79.96 |
| Support Level | $9.24 | $11.05 |
| Resistance Level | $10.35 | N/A |
| Average True Range (ATR) | 0.36 | 1.32 |
| MACD | 0.03 | 0.48 |
| Stochastic Oscillator | 67.75 | 94.94 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.